Relay Therapeutics, Inc. (RLAY) stock analysis
RLAY · Relay Therapeutics, Inc.
Latest recorded price: USD 17.27
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth 123.2%, free cash flow margin -1,536.1%, ROIC -54.0%. The model flags 2 risk signals for this company (1 high severity).
Similar companies in Healthcare
- Roivant Sciences Ltd. (ROIV)
- Royalty Pharma plc (RPRX)
- Revolution Medicines, Inc. (RVMD)
- Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
- Rhythm Pharmaceuticals, Inc. - Common Stock (RYTM)
- SELLAS Life Sciences Group, Inc. - Common Stock (SLS)
- Summit Therapeutics Inc. (SMMT)
- Syndax Pharmaceuticals, Inc. (SNDX)